Which pharmacologic agents are first‑line for bipolar depression, what alternatives should be used if lurasidone (Latuda) has already been tried, how should acute mania be managed, which second‑generation antipsychotics are preferred for a patient with a history of akathisia and how can akathisia be treated beyond propranolol and mirtazapine, how is drug‑induced parkinsonism recognized and managed, what steps are taken for treatment‑resistant schizophrenia after adequate trials of risperidone and olanzapine, and when should naltrexone versus acamprosate be chosen for alcohol use disorder based on medical history and contraindications?

Comprehensive Psychopharmacology Interview Guide

1. Bipolar Depression

For bipolar depression, start with quetiapine, lurasidone, or olanzapine-fluoxetine combination as first-line monotherapy, with lurasidone (40-60 mg daily) offering the best balance of efficacy and tolerability. 1, 2, 3

First-Line Options:

The FDA has approved only three agents for bipolar depression 1:

• Lurasidone (Latuda): 20-120 mg daily with food (≥350 calories)
• Quetiapine: Immediate or extended-release formulations
• Olanzapine-fluoxetine combination (OFC)

Efficacy comparison: All three have similar Number Needed to Treat (NNT) for response (4-7) and remission (5-7), with overlapping confidence intervals 3. However, lurasidone demonstrates superior tolerability with no adverse events having NNH <10, compared to OFC (weight gain NNH=6, diarrhea NNH=9) and quetiapine (somnolence NNH=3, dry mouth NNH=4) 3.

If Lurasidone Has Already Been Tried:

Switch to quetiapine or olanzapine-fluoxetine combination based on the patient's metabolic risk profile and urgency of response. 2, 3

• For high-urgency situations or prior good response: Consider OFC or quetiapine despite metabolic concerns 3
• For metabolically vulnerable patients: Quetiapine has moderate weight gain risk (NNH=16 for ≥7% weight gain) versus OFC (NNH=6) 3
• Alternative strategy: Add lurasidone to lithium or valproate if not already combined (NNH=36 for ≥7% weight gain) 3

Agents to AVOID:

Do not use lamotrigine (high switch risk, less robust efficacy), MAOIs, ziprasidone, aripiprazole, or risperidone as monotherapy—they lack efficacy evidence in bipolar depression. 2

Critical Monitoring:

• Manic switch risk: Monitor weekly during first month, especially with lurasidone 4
• Ensure adequate mood stabilizer coverage (lithium or valproate at therapeutic levels) before initiating any antidepressant or antipsychotic 5

---

2. Acute Mania Management

Initiate lithium, valproate, or a second-generation antipsychotic (aripiprazole, olanzapine, risperidone, quetiapine, or ziprasidone) as monotherapy for acute mania. 6, 7, 6

First-Line Monotherapy Options:

FDA-approved agents 6:

• Lithium (approved age ≥12 years)
• Valproate
• Second-generation antipsychotics: Aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone

Selection criteria 6:

1. Severity of psychotic symptoms (favor antipsychotics if prominent)
2. Rapid cycling presentation (favor valproate or lithium)
3. Side effect tolerance
4. Patient/family history of medication response
5. Availability of monitoring (lithium requires close lab monitoring)

Adjunctive Therapy:

• Benzodiazepines: For acute agitation and sleep disturbance in adults (caution in children—may cause disinhibition) 6
• Combination therapy: May add lithium or valproate to antipsychotic if monotherapy inadequate after 4 weeks 6

Avoid Unnecessary Polypharmacy:

Start with one agent and optimize before adding others. 6 Chlorpromazine is FDA-approved but not recommended as first-line due to side effect profile 6.

---

3. Antipsychotics and Akathisia

For patients with akathisia history, prefer quetiapine or clozapine; avoid aripiprazole and lurasidone which carry higher akathisia risk even at low doses. 8

Preferred Second-Generation Antipsychotics:

Lower akathisia risk:

• Quetiapine: Lowest akathisia rates among SGAs
• Clozapine: Minimal extrapyramidal symptoms (reserve for treatment-resistant cases) 9
• Olanzapine: Moderate-low akathisia risk

Higher akathisia risk to avoid:

• Aripiprazole: Partial dopamine agonist with significant akathisia risk even at introductory doses 8
• Lurasidone: Can cause severe akathisia at low doses (20-40 mg) 8
• Risperidone/paliperidone: Higher D2 occupancy increases risk

Akathisia Management Beyond Propranolol and Mirtazapine:

Pharmacologic options with evidence 10:

1. Lipophilic beta-blockers: Propranolol (30-90 mg/day) or pindolol (first-line)
2. Mirtazapine or mianserin: Serotonergic modulation (15-30 mg/day)
3. Benzodiazepines: Lorazepam 1-2 mg PRN or scheduled
4. Clonidine: Alpha-2 agonist (0.1-0.3 mg/day)
5. Trazodone: 50-150 mg/day

Non-pharmacologic strategies:

• Dose reduction of offending antipsychotic (first-line intervention) 10
• Switch to lower D2 affinity agent (quetiapine, clozapine) 10

Avoid routine anticholinergics—use only short-term for acute/severe symptoms when dose reduction and switching have failed 7.

---

4. Drug-Induced Parkinsonism

Recognize drug-induced parkinsonism by bradykinesia, rigidity, and tremor developing within weeks of antipsychotic initiation or dose increase; manage by dose reduction, switching to quetiapine/clozapine, or adding amantadine. 10

Recognition:

Clinical features:

• Bradykinesia (slowed movements)
• Rigidity (lead-pipe or cogwheel)
• Resting tremor (less common than idiopathic Parkinson's)
• Masked facies, shuffling gait
• Timing: Typically develops within 2-12 weeks of starting/increasing antipsychotic

Distinguish from idiopathic Parkinson's:

• Bilateral and symmetric presentation (vs. asymmetric in idiopathic)
• Temporal relationship to medication
• Absence of other parkinsonian features (anosmia, REM sleep disorder)

Management Algorithm:

Step 1: Dose reduction 10

• Reduce antipsychotic to lowest effective dose
• Reassess in 1-2 weeks

Step 2: Switch antipsychotic 10

• Preferred agents: Quetiapine or clozapine (lowest D2 affinity)
• Avoid high-potency D2 antagonists (haloperidol, risperidone)

Step 3: Add pharmacologic agent 10

• Amantadine: 100-300 mg/day (preferred over anticholinergics)
• Anticholinergics (biperiden, trihexyphenidyl): Only if amantadine ineffective
  • Use lowest effective dose
  • Avoid long-term use (cognitive impairment risk, especially elderly)
  • Taper and discontinue once symptoms resolve

Do NOT use anticholinergics routinely for prevention—only for treatment when other strategies fail 7.

---

5. Treatment-Resistant Schizophrenia

After two adequate trials of different antipsychotics (including risperidone and olanzapine at therapeutic doses for ≥4 weeks each with confirmed adherence), initiate clozapine as the definitive treatment for treatment-resistant schizophrenia. 9

Defining Treatment Resistance:

Criteria 9:

1. Persistent positive symptoms after two antipsychotic trials
2. Each trial: ≥4 weeks at therapeutic dose
3. Confirmed adherence (consider long-acting injectable if questionable)
4. Different pharmacodynamic profiles (e.g., risperidone then olanzapine)

Before Clozapine:

Reassess 9:

• Confirm schizophrenia diagnosis (rule out substance-induced, medical causes)
• Verify adherence (plasma levels, long-acting injectable trial)
• Optimize current antipsychotic dose
• Address comorbid substance use

Clozapine Initiation:

Dosing strategy 9:

• Titrate based on response and tolerability
• Target plasma level: ≥350 ng/mL initially
• If inadequate response at 12 weeks: increase to 550 ng/mL
• Above 550 ng/mL: Diminishing returns (NNT=17), increased seizure risk—only pursue in select cases 9

Mandatory monitoring:

• Absolute neutrophil count (ANC): Weekly for 6 months, then biweekly for 6 months, then monthly
• Metabolic parameters: Baseline and regular monitoring

Concurrent metformin: Always offer metformin prophylactically with clozapine to attenuate weight gain 9

If Clozapine Fails:

Consider clozapine augmentation strategies (beyond scope of initial question, but ECT and clozapine + another antipsychotic are options).

---

6. Alcohol Use Disorder: Naltrexone vs. Acamprosate

Choose naltrexone for patients with intact liver function who continue drinking or have strong cravings; choose acamprosate for patients with liver disease, those committed to abstinence, or when opioid medications are needed. 11

Efficacy Comparison:

Both agents reduce relapse risk 11:

• Acamprosate: Odds ratio 1.86 (95% CI 1.49-2.33) vs. placebo; 38% absolute abstinence probability (vs. 25% placebo)
• Naltrexone: Odds ratio 1.36 (95% CI 0.97-1.91) vs. placebo; 31% absolute abstinence probability
• Acamprosate + naltrexone combination: Odds ratio 3.68 (95% CI 1.50-9.02); 55% absolute abstinence probability 11

Acamprosate demonstrates slightly superior efficacy for maintaining complete abstinence 11, while naltrexone excels at reducing heavy drinking days.

Selection Based on Medical History:

Choose NALTREXONE when:

• Normal liver function (avoid if acute hepatitis or liver failure)
• Patient continues drinking or has difficulty achieving initial abstinence
• Strong alcohol cravings predominate
• Goal is harm reduction (reducing heavy drinking) rather than complete abstinence
• No current/anticipated opioid analgesic needs

Choose ACAMPROSATE when:

• Hepatic impairment (acamprosate renally cleared, safer in liver disease)
• Patient already abstinent or committed to complete abstinence
• Opioid medications needed for pain management (naltrexone contraindicated)
• Severe renal impairment is ABSENT (CrCl <30 mL/min is contraindication for acamprosate)
• Patient prefers TID dosing acceptable (vs. daily naltrexone)

Contraindications:

Naltrexone:

• Acute hepatitis or liver failure
• Current opioid use or anticipated need
• Opioid dependence (precipitates withdrawal)

Acamprosate:

• Severe renal impairment (CrCl <30 mL/min)
• Sulfa allergy (contains sulfate)

Combination Therapy:

Consider acamprosate + naltrexone combination for patients with severe alcohol use disorder and no contraindications—this provides superior efficacy (NNT ~3-4 for abstinence vs. placebo) 11.

Dropout Considerations:

Acamprosate has better treatment retention (odds ratio 0.73 for dropout vs. placebo) compared to naltrexone (0.70), though both are acceptable 11. Acamprosate's TID dosing may reduce adherence in some patients despite lower dropout rates in trials.